Kane Biotech Announces Trading on the OTCQB Venture Market
WINNIPEG, Manitoba, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced that effective February 1, 2018 shares of the Corporation have been approved for and will commence trading on the OTCQB Venture Market, operated by OTC Markets Group. Shares of Kane Biotech were already trading under the Pink® Open Market. With the upgrade to the OTCQB Venture Market, the shares will continue to trade under the ticker symbol “KNBIF.”
The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission. The OTCQB trading standards require that companies be current in their regulatory filings, that they complete an annual verification and management certification and have a minimum $0.01 bid price.
Mark Ahrens-Townsend, President & CEO of Kane Biotech, stated, “We’re happy to qualify and upgrade our listing with the OTC Markets. Growing our investor base and reaching more sophisticated investors is a key element of our investor relations efforts and trading on the QB tier is a significant step in raising Kane’s profile with investors.”
"We are delighted to welcome Kane Biotech to the OTCQB Venture Market,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “Kane Biotech joins an impressive roster of Canadian issuers that benefit from an efficient, cost-effective and less burdensome trading venue, broadening their access to the U.S. public markets. We look forward to supporting the company and its U.S. shareholders.”
The OTCQB Market is primarily for early-stage and developing U.S. and international companies that provides investors with higher reporting standards, increased analyst coverage and access to news services, and more comprehensive compliance requirements.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX:OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
About Kane Biotech Inc.
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (76 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Mark Ahrens-Townsend
President & CEO, Kane Biotech Inc.
ir@kanebiotech.com
+1 (204) 477-7592
Tirth Patel
Edison Advisors
Investor Relations
tpatel@edisongroup.com
+1 (646) 653-7035
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Released January 31, 2018